Roche Holding Announces Phase 2a Results for RGT-075 and Initiates Phase 2b Study in the US

Roche Holding has recently announced the Phase 2a topline results for RGT-075, an innovative oral once-daily small molecule GLP-1R agonist. This development marks a significant step forward in the treatment of obesity, showcasing Roche's commitment to addressing complex health challenges. Following these promising results, the company has initiated a Phase 2b study in the United States, aiming to further evaluate the efficacy and safety of RGT-075 in a larger patient population. This progression underscores Roche's dedication to advancing medical science and providing new therapeutic options for patients worldwide.